FDA’s Final Rule Clarifies De Novo Pathway For Device Makers

By Kelly Lienhard / October 5, 2021 at 1:02 PM

FDA on Monday (Oct. 4) published a final rule that clarifies how medical device makers can pursue marketing authorization through the agency’s De Novo pathway for new low- to moderate-risk devices for which there’s no existing predicate comparison device.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.